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FOLFIRI. CONCLUSIONS: FOLFOX appears to have favorable cost effectiveness 
compared to other agents in the treatment of stage IV colorectal cancer, even after 
factoring in the impact of generic irinotecan.
PODIUM SESSION I: DRUG UTILIZATION STUDIES
DU1
PHYSICAL FUNCTION AND THE CONCOMITANT USE OF
ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE 
INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA
Modi A1, Craig B1, Weiner M2, Sands L1, Thomas J1
1Purdue University, West Lafayette, IN, USA, 2Indiana University, Indiana University Center for 
Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA
OBJECTIVES: Antihistamines with anticholinergic properties (AA) are often used to
treat comorbidities in patients with dementia. Use of AA with cholinesterase inhibitors 
(CHI) may counteract beneﬁ ts of CHI in improving activities of daily living (ADL) or 
slowing ADL decline. Associations between use of AA with CHI and ADL function 
were assessed. METHODS: A retrospective cohort analysis of Indiana Medicaid 
claims and enrollment data from July 2001 through December 2005 merged with 
Minimum Data Set (MDS) identiﬁ ed persons q65 years, with dementia based on previ-
ously assessed criteria for identifying dementia and, receiving CHI. Persons taking 
anticholinergics other than AA during the study interval from ﬁ rst to last MDS assess-
ment during CHI use were excluded. Piecewise repeated measures analysis used days 
taking AA and days not taking AA during each assessment interval as predictors to
estimate inﬂ uence of AA use on MDS ADL function scores (range 0–28, higher scores 
 more dependence). Presence of shifts in curves and changes in slopes deﬁ ned changes 
in ADL. Age, gender, race, region, marital status and number of medications taken at 
the start of CHI use, Charlson comorbidity score and propensity score for receipt of 
AA were included as ﬁ xed covariates. RESULTS: A sample of 2,690 persons with 
mean age of 82 years, 75% female and, 90% white was identiﬁ ed. Of these, 691 
(26%) used AA. Overall, a 0.45 (p  0.02) upward shift in ADL score indicated an
immediate decrease in ADL function with AA use. Among persons with moderate 
ADL dependence (score 6–12), an increase in slope of 0.53 (p  0.04) per quarter also
was observed indicating faster decline with AA use. CONCLUSIONS: Use of AA with 
CHI is associated with greater ADL decline in Medicaid recipients with dementia. 
Potential impact of AA use on physical function should be considered before prescrib-
ing AA with CHI.
DU2
RACIAL DIAPARITIES AND BARRIER TO DRUG UTILIZATION IN
PATIENTS WITH DIABETES IN THE UNITED STATES
Seetasith A, Zhang JX
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: We sought to assess barriers to the appropriate statin usage measured
through out-of-pocket payment by insurance status and racial disparities in patients 
with diabetes. METHODS: We analyzed 1,708 civilian, non-institutionalized patients 
with diabetes aged between 20 and 85 in the 2003 Medical Expenditure Panel 
survey (MEPS), a nationally representative survey in the United States which was 
linked to drug utilization ﬁ les. We categorized patients with diabetes into six mutually
exclusive insurance groups. We performed bivariate chi-square tests to assess the 
association between race and statins use, and insurance status and statin use during 
the year. We further performed multivariate logistic regression analysis to assess the 
effect of race/ethnicity on statin usage for patients of different races/ethnicity, control-
ling for socioeconomic variables, and co-morbid conditions. RESULTS: Among the 
population, 369 (21.6%) were African American, 66 (3.9%) Asian and 396 (23.2%)
were Hispanic; the mean out-of-pocket payment per prescription of statins was $61.4
(SD $62.5) for Medicare patients, $24.0 (SD $43.7) for Medicaid patients, $ 25.4 (SD
$49.0) for patients with dual eligibility, $35.2 (SD $33.5) for those with private insur-
ance, $76.7 (SD $47.8) for those without insurance, and $83.9 (SD $90.5) for others. 
In bivariate analysis, statin usage was found to be signiﬁ cantly different across races 
and insurance status (p  0.020 and p  0.0001, respectively). In multivariate regres-
sion analysis, compared to White patients, African American patients were less likely 
to use statin (adjusted OR 0.57, 95% CI 0.43–0.76, p  0.0001). Asian and Hispanic 
patients were marginally less likely to use statin (adjusted OR 0.60, 95% CI 0.34–
1.05, p  0.078; and adjusted OR 0.75, 95% CI 0.56–1.00, p  0.055, respectively). 
CONCLUSIONS: Drug utilization is associated with insurance coverage. Racial/eth-
nicity disparity is observed in drug utilization of patients with diabetes after adjusting 
for insurance status.
DU3
PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH
CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE
ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
Vekeman F1, Laliberte F1, Afonja O2, Lafeuille MH1, Barghout V2, Duh MS3, Skarin AT4
1Groupe d’analyse, Ltee, Montréal, QC, Canada, 2Bayer HealthCare Pharmaceuticals, Inc, 
Wayne, NJ, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Dana-Farber Cancer Institute, 
Boston, MA, USA
OBJECTIVES: Pegﬁ lgrastim is a long-acting granulocyte colony-stimulating factor 
(G-CSF) used to prevent or treat febrile neutropenia associated with myelosuppressive
anticancer therapies. According to the prescribing information, pegﬁ lgrastim should
not be administered within 14 days before or 24 hours after cytotoxic chemotherapy 
because of the potential for myeloid toxicity. This study examined use patterns of 
pegﬁ lgrastim in real-life practice. METHODS: Analysis of health insurance claims
data in 2000–2007 from 35 large health plans across the US was conducted. Patients 
who had a cancer diagnosis and chemotherapy within 120 days of their ﬁ rst pegﬁ l-
grastim injection were identiﬁ ed. The proportion of pegﬁ lgrastim injections that were
followed by administration of chemotherapy within 11 and 9 days was calculated.
Analysis was also stratiﬁ ed by cancer type [Non-Hodgkin’s lymphoma (NHL), lung, 
and breast]. RESULTS: A total of 13,526 cancer patients received 57,118 pegﬁ lgrastim 
injections. NHL, lung, and breast cohorts comprised 2,722, 2,772, and 4,955 patients, 
respectively. Mean age (SD) was 55.0 (11.6) and women represented 65.9% of study
population. Among all cancer types, 19.2% of pegﬁ lgrastim injections had a chemo-
therapy claim within the following 11 days. This pattern of use was the highest in 
NHL (18.9%), followed by lung (17.1%), and breast (16.2%). Similar results were 
observed in the 9-day sensitivity analysis (all cancer: 16.2%, NHL: 17.4%, lung: 
16.0%, breast: 14.7%). CONCLUSIONS: Based on the retrospective analysis of this 
administrative claims database, the use of pegﬁ lgrastim within 11 days of an admin-
istration of chemotherapy was observed in 15–20% of cases which is inconsistent with
the recommended guidelines. Pegﬁ lgrastim use in these situations may have the poten-
tial to increase sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.
Further research is being conducted to assess the related clinical and economic impact 
of this pattern of usage.
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PM1
PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT
Meckley LM, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: Personalized medicine (PM) has attracted tremendous interest, but 
yielded few marketed products. We examined factors inﬂ uencing the approval, cover-
age, and reimbursement of existing PM technologies. METHODS: We conducted six 
case studies of paired genetic tests and treatments in order to develop a framework 
to explain differences in adoption and reimbursement. We divided these case studies 
into three groups based on the purpose of the PM technology: Disease differentiation 
(HER2/neu with Herceptin (trastuzumab), hepatitis C genotyping with ribavirin/
pegylated interferon, and Oncotype DX with chemotherapy); pharmacogenetics
(UGT1A1 with irinotecan (Camptosar) and VKORC1/CYP2C9 with warfarin) and 
predisposition tests (BRCA 1/2 with prophylactic surgical measures and Oncotype DX
with chemotherapy). RESULTS: The factors inﬂ uencing approval, coverage and reim-
bursement appear based broadly on the purpose of, and evidence for, the PM technol-
ogy, rather than the type of device regulation (i.e., PMA, CLIA or 510(k)). Disease
differentiation test reimbursement is more widespread than other PM tests because 
of better evidence, guidelines, and clinician preferences. Predisposition tests may be 
reimbursed, despite the lack of randomized clinical trials, because people may value
the information from testing, regardless of the clinical consequences. Pharmacogenet-
ics (PGx) faces reimbursement hurdles because of the lack of evidence about clinical 
utility, though some companies bypass payers, and market PGx tests directly to con-
sumers. An additional challenge for all PM is the cumbersome existing coding system 
for reimbursement and the lack of value-based arrangements. CONCLUSIONS: To 
date, the promise and hype of PM has outpaced its evidentiary support. In order to
achieve favorable coverage and reimbursement and to support premium prices for
PM, manufacturers will need to bring better clinical evidence to the marketplace 
and develop better support for the value of their products. More ﬂ exible reim-
bursement systems are needed to reward PM technologies that demonstrate evidence
of value.
PM2
IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING
ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS
Hughes DA1, Al-Zubiedi S2, Hanson A2, Jorgensen A2, Pirmohamed M2
1Bangor University, Bangor, UK, 2University of Liverpool, Liverpool, UK
OBJECTIVES: The anticoagulant effect of warfarin is subject to wide dose variability
that may lead to hemorrhagic and thrombotic events. Variations in the CYP2C9 and 
VKORC1 genes together with clinical factors explain approximately 50% of this 
variability. The aim was to estimate the health care resource use, and overall costs
associated with therapy from the perspective of the UK NHS. METHODS: As part 
of a 6-month prospective cohort study evaluating pharmacogenetic and clinical factors 
associated with warfarin therapy, patients’ use of resources were recorded and costs
valued (UK a for 2006/7). Resource use was compared among patient sub-groups
(deﬁ ned by age; gender; CYP2C9 genotype; VKORC1 genotype; adverse events; co-
medication; co-morbidities; and smoking status). Mean costs were calculated with
95%CI estimated using non-parametric bootstrap sampling. RESULTS: Complete 
data were available for 254 patients. During the study period a total of 930 antico-
agulation visits (median 3 per patient, IQR 1, 5) and 4059 INR measurements (median 
15, IQR 10, 20) were recorded. Of the 70 patients who had experienced an adverse 
event, 16 (6.3%) required hospitalisation. Controlling for age, gender, and co-morbidi-
ties in patients who experienced an adverse event, the OR for hospitalization was 8.35 
